Today: 29 April 2026
Browse Category

NASDAQ:PTCT 25 August 2025 - 28 November 2025

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······

Stock Market Today

  • Element Solutions Beats Q1 Earnings and Revenue Estimates on Strong Electronics Demand
    April 29, 2026, 10:01 AM EDT. Element Solutions Inc. (ESI) reported first-quarter 2026 earnings of 41 cents per share, excluding one-time items, beating the Zacks Consensus Estimate of 38 cents. Net sales rose 41% year over year to $840 million, surpassing the consensus of $744.4 million, driven by strong demand in its Electronics segment for AI infrastructure and high-performance electronics. The Electronics segment's organic net sales grew 15%, with adjusted EBITDA up 34%. However, net income fell 43% year on year to $56 million due to prior-year gains. ESI's cash decreased substantially, and debt rose to $2.06 billion. The company raised its full-year adjusted EBITDA outlook to $665 million-$685 million. Shares have surged 91.7% over the past year, outperforming the industry rise of 9.8%, while maintaining a Zacks Rank #3 (Hold).

Latest article

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

29 April 2026
Lemonade Inc reported first-quarter revenue of $258 million, up 71% from a year earlier, and narrowed its net loss to $35.8 million, or 47 cents a share. Shares rose 5.6% in premarket trading after results beat estimates. In-force premium climbed 32% to $1.33 billion, with customers up 23% to 3.14 million. The company raised its 2026 outlook and now expects full-year revenue of up to $1.203 billion.
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Biogen lowered its 2026 adjusted earnings forecast to $14.25–$15.25 per share, citing research and development charges from recent acquisitions. First-quarter revenue rose 2% to $2.48 billion, with adjusted earnings of $3.57 per share, beating analyst estimates. Leqembi sales climbed 74% to $168 million globally.
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Go toTop